This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Innovations of Hideaki Shimada in Antibody Development
Introduction
Hideaki Shimada is a notable inventor based in Singapore, recognized for his contributions to the field of biotechnology. He has developed innovative solutions that address critical challenges in medical science. His work primarily focuses on the development of antibodies that can effectively target specific proteins involved in various diseases.
Latest Patents
One of Hideaki Shimada's significant patents is titled "Cross-species anti-latent TGF-beta 1 antibodies and methods of use." The objective of this invention is to provide cross-species anti-latent TGF-beta 1 antibodies that inhibit a protease-mediated activation of latent TGF-beta 1 without affecting integrin-mediated activation. To achieve this, anti-latent TGF-beta 1 antibodies were screened, humanized, and optimized. This invention also includes combination therapies that incorporate an anti-latent TGF-beta 1 antibody along with one or more immune checkpoint inhibitors, preferably PD-1 axis binding antagonists. Hideaki Shimada holds 1 patent related to this groundbreaking work.
Career Highlights
Hideaki Shimada is associated with Chugai Seiyaku Kabushiki Kaisha, a prominent company in the pharmaceutical industry. His role at the company has allowed him to contribute significantly to research and development in antibody therapies. His innovative approach has positioned him as a key figure in the advancement of therapeutic solutions.
Collaborations
Throughout his career, Hideaki Shimada has collaborated with esteemed colleagues, including Masakazu Kanamori and Xing'er Christine Koo. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their respective fields.
Conclusion
Hideaki Shimada's work in developing cross-species anti-latent TGF-beta 1 antibodies exemplifies the impact of innovative thinking in biotechnology. His contributions continue to influence the landscape of medical research and therapeutic development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile